Title |
Treatment of end-stage renal disease with continuous ambulatory peritoneal dialysis in rural Guatemala
|
---|---|
Published in |
BMJ Case Reports, April 2018
|
DOI | 10.1136/bcr-2017-223641 |
Pubmed ID | |
Authors |
Jillian Moore, Pablo Garcia, Peter Rohloff, David Flood |
Abstract |
A 42-year-old indigenous Maya man presented to a non-profit clinic in rural Guatemala with signs, symptoms and laboratory values consistent with uncontrolled diabetes. Despite appropriate treatment, approximately 18 months after presentation, he was found to have irreversible end-stage renal disease (ESRD) of uncertain aetiology. He was referred to the national public nephrology clinic and subsequently initiated home-based continuous ambulatory peritoneal dialysis. With primary care provided by the non-profit clinic, his clinical status improved on dialysis, but socioeconomic and psychological challenges persisted for the patient and his family. This case shows how care for people with ESRD in low- and middle-income countries requires scaling up renal replacement therapy and ensuring access to primary care, mental healthcare and social work services. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 10% |
Guatemala | 1 | 10% |
United States | 1 | 10% |
Unknown | 7 | 70% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 63 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 14% |
Student > Master | 7 | 11% |
Student > Bachelor | 7 | 11% |
Student > Ph. D. Student | 5 | 8% |
Student > Doctoral Student | 3 | 5% |
Other | 10 | 16% |
Unknown | 22 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Nursing and Health Professions | 14 | 22% |
Medicine and Dentistry | 11 | 17% |
Psychology | 6 | 10% |
Social Sciences | 4 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 4 | 6% |
Unknown | 22 | 35% |